Antonella Chiavassa
| Titolo | Pubblicato in | Anno |
|---|---|---|
| Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis | BMC CANCER | 2024 |
| Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis | BMC CANCER | 2024 |
| Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach | CANCER IMMUNOLOGY, IMMUNOTHERAPY | 2023 |
| 127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma | ANNALS OF ONCOLOGY | 2022 |
| The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy | FRONTIERS IN IMMUNOLOGY | 2022 |
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma